The Miami Stem Cell Therapy Podcast Titelbild

The Miami Stem Cell Therapy Podcast

The Miami Stem Cell Therapy Podcast

Von: miamistemcelltherapy
Jetzt kostenlos hören, ohne Abo

Nur 0,99 € pro Monat für die ersten 3 Monate

Danach 9.95 € pro Monat. Bedingungen gelten.

Über diesen Titel

The Miami Stem Cell Podcast by STEMS Health Regenerative Medicine in Miami Beach, Florida, is an informational, synthetic narrated podcast designed to educate listeners about the science and practice of regenerative medicine. Each episode delivers clear, evidence-based insights on topics such as stem cell therapy, PRP, exosomes, peptides, and anti-aging innovations, reflecting the clinical expertise of Dr. Ankeet Choxi and Dr. Jarred Mait. Created for patients and wellness-minded listeners, the podcast simplifies complex medical topics while emphasizing safety, transparency, and real-world applications - helping you stay informed about the latest advances in regenerative and longevity medicine. To learn more about regenerative and restorative treatments, visit stemshealthregenerativemedicine.com or schedule a consultation at our Miami Beach clinic, located at 925 W 41st St #300A, Miami Beach, FL 33140, (305) 677.0565.

Copyright 2025 All rights reserved. Hygiene & gesundes Leben
Folgen
  • Ep 15 Dr. Mari Dezawa — MUSE Cell Innovations Founder and CSO

    Ep 15 Dr. Mari Dezawa — MUSE Cell Innovations Founder and CSO
    Dec 23 2025
    A profile of Dr. Mari Dezawa, whose discovery of MUSE Cells reshaped how regenerative medicine understands stress-enduring, pluripotent-like cells and their potential to support targeted joint and spine repair. To learn more about regenerative and restorative treatments, visit stemshealthregenerativemedicine.com or schedule a consultation at our Miami Beach clinic, located at 925 W 41st St #300A, Miami Beach, FL 33140, You can also reach us by phone at (305) 677.0565. FULL TRANSCRIPT Dr. Mari Dezawa is one of the most influential figures in modern regenerative medicine. As Chief Scientific Officer of MUSE Cell Innovations and a professor at Tohoku University in Japan, she has reshaped the field through her groundbreaking discovery of MUSE Cells - multilineage-differentiating stress-enduring cells. Her work has provided a safer, more targeted alternative to embryonic and induced pluripotent stem cells, without the associated ethical or safety concerns. MUSE Cells are now at the center of a growing number of therapies focused on orthopedic and spine-related repair. So what exactly are MUSE Cells, and why do they matter? MUSE Cells are a rare type of adult stem cell found in bone marrow and umbilical cord tissue. They make up only one to two percent of mesenchymal stem cells, but they exhibit extraordinary properties. They survive harsh cellular stress. They can differentiate into all three germ layers - just like pluripotent cells. And most importantly, they do not form tumors. These characteristics are what make MUSE Cells so valuable. They offer the potential to regenerate tissue in a highly controlled way while reducing safety risks that have long slowed the adoption of stem cell-based treatments. One of the keys to understanding MUSE Cells is their identification. Dr. Dezawa’s team isolated them using a specific surface marker called SSEA-3. These cells can endure conditions that would destroy most other cells, and that’s where their name comes from: stress-enduring. They’ve been shown to differentiate into cell types across the ectodermal, mesodermal, and endodermal lines, supporting tissues ranging from nerve to muscle to cartilage. But unlike embryonic stem cells or iPSCs, they do so without forming teratomas or requiring genetic manipulation. So how do they work in practice? One of the most important clinical features of MUSE Cells is their ability to home to sites of injury. Whether delivered locally or systemically, they seek out damaged or inflamed tissue. Once there, they can either integrate and differentiate, or secrete beneficial factors that reduce inflammation and support surrounding cells. This is particularly relevant in orthopedic and spine care. Studies suggest MUSE Cells may support healing in the knees, hips, shoulders, and spine - areas where tissue damage is often slow to repair. Instead of simply reducing inflammation, they offer cellular-level restoration. This precision is what separates MUSE therapy from more traditional mesenchymal stem cell approaches. Where bulk MSCs may function broadly and non-specifically, MUSE Cells target the exact areas where healing is most needed, bringing structural support and regenerative signals. Dr. Dezawa’s work has moved beyond the lab and into clinical care. Through her partnership with MCI - Muse Cell Innovations - licensed providers are now offering MUSE Cell therapy in orthopedic settings. One such provider is STEMS Health in Miami Beach, one of only a few Florida clinics authorized to administer authentic Dezawa MUSE Cells. Treatments focus on joint and spine injections guided by ultrasound. No IV infusions are offered. Instead, therapy is highly localized, and delivered in a way that aligns with the scientific properties of the cells. As Chief Scientific Officer, Dr. Dezawa continues to lead the advancement of MUSE Cell research. Her team is working on GMP-compliant production lines, large-scale validation studies, and peer-reviewed research exploring how these cells can benefit not just orthopedics, but neurology, immunology, and more. Her legacy is still in progress. But what’s clear is that Dr. Mari Dezawa has introduced a new level of precision, safety, and therapeutic potential into regenerative medicine. Here are a few quick answers to common questions. What makes Dr. Dezawa’s discovery unique? She identified a subset of adult stem cells with pluripotent-like behavior that can aid tissue repair without the risks associated with iPSCs or embryonic stem cells. Are MUSE Cells safer than traditional pluripotent stem cells? Yes. MUSE Cells are non-tumorigenic and do not require genetic reprogramming, offering a more stable path to therapeutic use. Do they replace traditional MSCs? No. They complement them. MUSE Cells offer greater targeting and regenerative endurance, but MSCs remain useful in broader applications. Can they treat spine and joint issues? Current clinical use includes orthopedic pain, joint degeneration, ...
    Mehr anzeigen Weniger anzeigen
    7 Min.
  • Ep 14 Adult Stem Cells for Advanced Dry Macular Degeneration

    Ep 14 Adult Stem Cells for Advanced Dry Macular Degeneration
    Dec 22 2025
    A look at emerging clinical research showing how adult stem cell transplantation may offer early visual improvements and a new therapeutic pathway for patients with advanced dry AMD and geographic atrophy. To learn more about regenerative and restorative treatments, visit stemshealthregenerativemedicine.com or schedule a consultation at our Miami Beach clinic, located at 925 W 41st St #300A, Miami Beach, FL 33140, You can also reach us by phone at (305) 677.0565. FULL TRANSCRIPT Dry age-related macular degeneration, also known as dry AMD, is one of the most common causes of irreversible vision loss in adults over 65. Its advanced form, called geographic atrophy, leads to the progressive breakdown of retinal cells and has few effective treatment options. Unlike wet AMD, which can be managed with injections, advanced dry AMD lacks therapies that can restore lost vision. This has created an urgent need for new solutions - and that’s where adult stem cells may come in. Emerging research suggests that adult stem cell transplantation could offer a new path forward. Rather than simply slowing disease progression, stem cell therapies are being studied for their ability to support visual function and preserve retinal structure. Let’s take a closer look at why adult stem cells are drawing so much interest in this area. Adult stem cells, including mesenchymal stem cells and retinal progenitor cells, are known for their anti-inflammatory and immune-modulating properties. They can be ethically sourced from bone marrow or umbilical tissue and do not carry the tumor risks associated with embryonic or pluripotent stem cells. In animal models, these cells have been shown to preserve photoreceptors, reduce inflammation in the eye, and even improve visual responses. This laid the groundwork for early human trials. Several small, early-phase clinical studies have explored subretinal injections of these cells in patients with geographic atrophy. So far, results are cautiously optimistic. Most trials have reported no serious safety issues. And in some cases, participants experienced modest improvements in visual acuity or contrast sensitivity over the course of 6 to 12 months. Imaging studies have also shown stabilization in areas of retinal atrophy, suggesting the potential for real biological impact. How do these cells work? One mechanism is paracrine signaling - where the transplanted cells don’t necessarily become new retinal cells, but instead release beneficial signals. These may enhance the survival of photoreceptors, protect the retinal pigment epithelium, and regulate inflammation. In some cases, retinal progenitor cells may even integrate into retinal layers and contribute to structural repair. The preferred method of delivery is subretinal injection, placing the cells directly into the space between the retina and its supporting layer. This ensures close contact with damaged tissue while minimizing systemic exposure and the risk of unwanted cell migration. Innovations like image-guided microinjections have improved safety and precision in these procedures, reducing the risk of complications. Of course, stem cell therapy isn’t without its challenges. Ensuring consistent quality and viability of cell batches - especially for off-the-shelf or donor-based products - is critical. Long-term durability of the benefits is still being studied. And researchers are working to identify reliable biomarkers to track whether the therapy is truly working. Most trials now include rigorous visual testing, OCT imaging, and biomarker analysis over one to two years. Regulatory agencies, including the FDA, require this kind of detailed validation before allowing stem cell therapies to move into broader use. So what comes next? Larger phase 2 trials are now underway, aiming to confirm the early signals seen in smaller studies. Some research is exploring combination approaches - pairing stem cells with gene therapies or drugs that target other parts of the disease pathway. Others are looking at personalized stem cell lines for use in high-risk individuals. And with the help of AI-assisted retinal imaging, physicians may soon be able to detect changes earlier and tailor treatment more precisely to each patient. While stem cells for dry AMD are still investigational, their potential is significant. For patients with few existing options, they represent a new frontier in vision care - one focused not just on slowing loss, but on supporting real regeneration. Here are a few frequently asked questions. Are stem cells currently FDA-approved for dry AMD? No. These therapies are still being studied and are not yet approved for routine clinical use. How are the cells delivered? Most studies use subretinal injection, placing the cells directly behind the retina near areas of damage. Can stem cells actually improve vision? Some trials have shown improvements in vision and retinal structure, but larger studies are needed to confirm these ...
    Mehr anzeigen Weniger anzeigen
    7 Min.
  • Ep 13 FDA’s Evolving Pipeline of iPSC and MSC Products

    Ep 13 FDA’s Evolving Pipeline of iPSC and MSC Products
    Dec 19 2025
    An overview of how new FDA clearances for iPSC-derived and MSC-based therapies indicate growing regulatory maturity, clearer translational pathways, and expanding commercialization potential for next-generation cell products. To learn more about regenerative and restorative treatments, visit stemshealthregenerativemedicine.com or schedule a consultation at our Miami Beach clinic, located at 925 W 41st St #300A, Miami Beach, FL 33140, You can also reach us by phone at (305) 677.0565. FULL TRANSCRIPT Regenerative medicine is moving into a new era. Once dominated by experimental applications and regulatory gray zones, today’s landscape is defined by FDA-cleared products, structured trial pathways, and tighter manufacturing oversight. At the center of this shift are cell-based therapies built around two core technologies: induced pluripotent stem cells, or iPSCs, and mesenchymal stem cells, or MSCs. The FDA has already cleared dozens of therapies using or related to these cell types. This includes products like Ryoncil for pediatric graft-versus-host disease, Allocord for hematologic disorders, and MACI, used to treat cartilage injuries in the knee. These approvals signal something bigger: regulatory maturity. The FDA is actively shaping pathways to clinical use - through formal guidance, standardized testing, and accelerated programs like the Regenerative Medicine Advanced Therapy designation. Let’s break down how iPSC and MSC therapies differ and why they’re so important. iPSCs are adult cells that have been reprogrammed to act like embryonic stem cells. They can become nearly any type of cell - cardiac, neural, retinal, and more. This flexibility makes them ideal for targeted cell replacement therapies, especially in complex diseases like macular degeneration or Parkinson’s. MSCs, by contrast, are naturally multipotent. Found in bone marrow, fat, and umbilical cord tissue, these cells don’t require genetic engineering. They’re known for their ability to modulate the immune system, reduce inflammation, and support tissue repair. That makes them particularly valuable in orthopedics and inflammatory conditions. While MSCs are more common in current FDA approvals, iPSCs are gaining ground. Early-phase trials are evaluating iPSC-derived retinal cells, cardiomyocytes, and nerve-supporting cells. Many gene and cell therapies now in development incorporate iPSC technology behind the scenes. The FDA’s Center for Biologics Evaluation and Research, or CBER, has taken several steps to support these innovations. This includes guidance documents covering everything from potency testing and donor screening to good manufacturing practices. Under FDA regulations, both iPSC and MSC therapies must meet strict standards before they reach patients. That means proving cell identity, biological potency, safety, and sterility. Manufacturers are required to run viability assays, confirm genetic stability, test for contamination, and operate in certified GMP labs. For iPSCs, the risk of uncontrolled growth or tumor formation requires even more scrutiny. But regulatory clarity is only part of the story. The commercial landscape is also evolving. We’re seeing an increase in off-the-shelf allogeneic products like Ryoncil, which offer scalable access to care without requiring a custom donor for every patient. Combination therapies - pairing cells with scaffolds or delivery devices - are also becoming more common, especially in orthopedics. Another shift is happening in clinical access. Decentralized trial networks are expanding the reach of investigational therapies. Patients who don’t live near a major academic center may still be eligible to participate in early access programs. Altogether, these developments suggest that cell-based therapies are moving from niche to mainstream. For patients, this means more options and a clearer understanding of what’s available - and what’s still being studied. For providers, it means better tools, more data, and the chance to align treatment with individual patient biology. Let’s wrap up with a few key questions. What’s the difference between iPSC and MSC therapies? iPSCs are reprogrammed to become nearly any cell type and are often used in precise replacement therapies. MSCs are naturally multipotent and valued for immune modulation and tissue repair, especially in orthopedic use. Are any iPSC-based therapies FDA-approved? Most FDA-cleared therapies currently involve MSCs or related platforms. iPSC-based products are primarily in trial phases but are moving closer to approval. What is RMAT designation? The FDA’s Regenerative Medicine Advanced Therapy designation offers fast-track support for promising cell therapies showing early clinical benefit. How are these products manufactured safely? They must meet strict FDA standards for identity, potency, sterility, and safety - and must be produced in certified GMP-compliant facilities. What are today’s top uses...
    Mehr anzeigen Weniger anzeigen
    7 Min.
Noch keine Rezensionen vorhanden